Literature DB >> 15737555

The potential of statins as part of anti-cancer treatment.

Stefan Sleijfer1, Ate van der Gaast, André S Th Planting, Gerrit Stoter, Jaap Verweij.   

Abstract

Statins are known to reduce mortality related to cardiovascular diseases. In recent years, evidence has accumulated that statins also exert anti-tumour activity for which numerous potential underlying mechanisms of action have been suggested. Accordingly, several case-control studies showed a reduction in cancer incidence in patients treated with statins. Furthermore, statins interact synergistically with several anti-tumour treatments in preclinical studies. Until now, only a few clinical studies are available that explore the optimal dose, feasibility, and efficacy of statins applied as single agents to control the growth of existing tumours. Studies investigating statins as part of a multi-drug regimen are completely lacking. Nevertheless, the interesting pre-clinical anti-tumour activity of statins combined with a favourable toxicity profile warrant their further development as anti-tumour agents, in particular as part of multi-drug regimens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15737555     DOI: 10.1016/j.ejca.2004.12.009

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  25 in total

Review 1.  Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis.

Authors:  Judith M Graber; Shou-En Lu; Yong Lin; Grace Lu-Yao; Xiang-Lin Tan
Journal:  Curr Med Chem       Date:  2018       Impact factor: 4.530

2.  Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study.

Authors:  Jian-Yu E; Shou-En Lu; Yong Lin; Judith M Graber; David Rotter; Lanjing Zhang; Gloria M Petersen; Kitaw Demissie; Grace Lu-Yao; Xiang-Lin Tan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-06-15       Impact factor: 4.254

3.  The evidence on trial: cholesterol lowering and cancer.

Authors:  A M Tonkin; A Forbes; S J Haas
Journal:  Heart Asia       Date:  2009-01-01

4.  A regenerable sorbent composed of a zeolite imidazolate framework (ZIF-8), Fe3O4 and graphene oxide for enrichment of atorvastatin and simvastatin prior to their determination by HPLC.

Authors:  Jun Peng; Huairu Tian; Qiuzheng Du; Xuanhong Hui; Hua He
Journal:  Mikrochim Acta       Date:  2018-01-27       Impact factor: 5.833

5.  Statins inhibit the growth of variant human embryonic stem cells and cancer cells in vitro but not normal human embryonic stem cells.

Authors:  K Gauthaman; N Manasi; A Bongso
Journal:  Br J Pharmacol       Date:  2009-05-11       Impact factor: 8.739

6.  Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

Authors:  Anke J Roelofs; Claire M Edwards; R Graham G Russell; F Hal Ebetino; Michael J Rogers; Philippa A Hulley
Journal:  J Pharmacol Exp Ther       Date:  2007-04-05       Impact factor: 4.030

7.  Ginsenoside Rg3 micelles mitigate doxorubicin-induced cardiotoxicity and enhance its anticancer efficacy.

Authors:  Lan Li; Jingyu Ni; Min Li; Jingrui Chen; Lifeng Han; Yan Zhu; Deling Kong; Jingyuan Mao; Yi Wang; Boli Zhang; Meifeng Zhu; Xiumei Gao; Guanwei Fan
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 8.  Anti-tumor effect of statin on pancreatic adenocarcinoma: From concept to precision medicine.

Authors:  Chung-Tsui Huang; Yao-Jen Liang
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

9.  Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells.

Authors:  Martin Werner; Bihter Atil; Evelyn Sieczkowski; Peter Chiba; Martin Hohenegger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-07       Impact factor: 3.000

10.  Statin use and association with colorectal cancer survival and risk: case control study with prescription data linkage.

Authors:  Fatim Lakha; Evropi Theodoratou; Susan M Farrington; Albert Tenesa; Roseanne Cetnarskyj; Farhat V N Din; Mary E Porteous; Malcolm G Dunlop; Harry Campbell
Journal:  BMC Cancer       Date:  2012-10-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.